MustGrow Biologics reports positive field trial results for TerraMG in canola production

MustGrow Biologics (TSX-V:MGRO, OTCQB:MGROF) reported positive two-year field trials of its mustard-derived biocontrol TerraMG on ~100 acres of Canadian canola showing reductions in clubroot resting spore concentrations (up to 95% in 2024) and yield uplifts up to 7 bu/acre (≈$91/acre); 2025’s drier conditions produced smaller gains of 1–2 bu/acre. TerraMG releases naturally occurring isothiocyanates and MustGrow is pursuing registration through Health Canada’s PMRA to address an unmet control option for clubroot in canola (Canada production ~21.8 Mt, ~$14bn value in 2025). While results are promising for potential commercialization and ESG-friendly disease control, near-term commercial and share-price impact is limited given the small trial scale, variable disease pressure and pending regulatory approval.

Analysis

Market structure: TerraMG positions MustGrow (MGROF/OTCQB) as a niche winner—early commercial traction addresses an unmet Clubroot control need in a ~$14B Canadian canola market. Direct beneficiaries include MustGrow, NexusBioAg distribution partners, and mustard seed-meal suppliers; large agrichemicals see limited near-term downside because registered chemical alternatives and resistant varieties still dominate. If TerraMG delivered a modest 1–3 bu/acre average lift on 10% adoption, that implies farm-level upside in the low hundreds of millions CAD—material for MGROF but immaterial to global agrochem majors.

Risk assessment: Key downside is regulatory (Health Canada PMRA) delay or additional trial requirements; expect 12–24 months to full registration under base case, with a 20–40% chance of extended trials as a tail. Operational risks are high: efficacy is weather-dependent (2024 wet vs 2025 dry variance), pathotype evolution could erode benefit, and MGROF faces capital/dilution risk to scale manufacturing of mustard meal. Catalysts that change trajectory: positive PMRA conditional approval (accelerator), large-scale independent replication (accelerator), or a failed registration/negative replicate (binary downside).

Trade implications: Tactical idea—establish a small proof position in MGROF (2–3% of risk capital) given binary upside on registration, with a hard stop at -50% and scale up to 5% on conditional PMRA approval within 12 months. For diversified exposure, buy a 12–18 month bullish call spread on Nutrien (NTR) to capture distribution upside (allocate 1% of risk capital; example long Jan-2027 call/short higher strike). Avoid large longs in major agrochemicals; instead hedge adoption risk by keeping crop exposure hedges (canola futures/options) until 1) independent multi-year replication reported or 2) PMRA clears product.

Contrarian angles: Market likely understates execution, but also may be underestimating adoption friction—farmers rely on rotations/resistant seed and may adopt slowly; pricing power for a commodity-based input will be weak. M&A is a plausible upside if MGROF proves consistent efficacy (acqui-hire by a major or distributor within 12–36 months), creating asymmetric payoff for small, patient stakes. Close positions if replicated yield improvements fall below 1 bu/acre across independent trials or if PMRA requires multicrop/long-term ecotoxicology studies (negative triggers).

Key Decisions for Investors

• Initiate a tactical long position in MGROF (OTCQB:MGROF) sized at 2–3% of discretionary risk capital; set a stop-loss at -50% and a time-based review at 6 months. Increase to 5% total if Health Canada PMRA grants conditional registration within 12 months.
• Allocate 1% of portfolio to a 12–18 month bullish call spread on Nutrien (NTR) to capture upside from distributor-led rollouts (example: buy Jan-2027 call / sell a higher strike call to cap cost). Close or roll if NexusBioAg distribution announcements expand to >5M acres target or if MGROF fails PMRA milestones.
• Do not increase exposure to large agrochemical manufacturers (e.g., CTVA, FMC) on the basis of this news; instead reduce short-term canola price-hedges for grain producers by up to 10–20% only after conditional registration is confirmed and independent multi-site trials (≥3 sites, ≥2 years) show ≥2 bu/acre average benefit.
• Monitor three short-term triggers: PMRA submission/decision status within 90 days, publication of independent multi-site 2026 trial results within 6–12 months, and any supply agreements with major distributors; if any trigger is negative (failed PMRA, replication <1 bu/acre, or no distribution deals within 12 months), liquidate MGROF position.